tiprankstipranks
C4 Therapeutics Initiates Stock Option Repricing for Retention
PremiumCompany AnnouncementsC4 Therapeutics Initiates Stock Option Repricing for Retention
2M ago
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
PremiumPress Releases
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
2M ago
C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA
PremiumCompany Announcements
C4 Therapeutics Strikes Major Oncology Deal with Merck KGaA
2M ago
New Debt & Financing Risk for C4 Therapeutics, Inc. – What’s the Latest?
PremiumCompany AnnouncementsNew Debt & Financing Risk for C4 Therapeutics, Inc. – What’s the Latest?
2M ago
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PremiumPress Releases
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2M ago
C4 Therapeutics upgraded to Neutral from Underweight at JPMorgan
PremiumThe Fly
C4 Therapeutics upgraded to Neutral from Underweight at JPMorgan
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100